{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:17:24Z","timestamp":1776205044116,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejso.2022.04.011","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T20:14:40Z","timestamp":1650917680000},"page":"1994-2001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer"],"prefix":"10.1016","volume":"48","author":[{"given":"Alessandro","family":"Cucchetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7370-1508","authenticated-orcid":false,"given":"Stefano","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2905-1146","authenticated-orcid":false,"given":"Elton","family":"Dajti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Binda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9654-7243","authenticated-orcid":false,"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4334-5167","authenticated-orcid":false,"given":"Giorgio","family":"Ercolani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2022.04.011_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/bjs.10870","article-title":"Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer","volume":"105","author":"Versteijne","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2022.04.011_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1200\/JCO.2016.68.5081","article-title":"Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis","volume":"35","author":"Mokdad","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2022.04.011_bib3","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/SLA.0000000000005126","article-title":"Neoadjuvant therapy for resectable pancreatic cancer: a new standard of care. Pooled data from 3 randomized controlled trials","volume":"274","author":"Birrer","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2022.04.011_bib4","series-title":"Cochrane Handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.ejso.2022.04.011_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ejso.2022.04.011_bib6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12874-020-01169-7","article-title":"Using Trial Sequential Analysis for estimating the sample sizes of further trials: example using smoking cessation intervention","volume":"20","author":"Claire","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejso.2022.04.011_bib7","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jclinepi.2012.11.007","article-title":"Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error","volume":"66","author":"Miladinovic","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ejso.2022.04.011_bib8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jclinepi.2008.08.010","article-title":"Updating meta-analyses leads to larger type I errors than publication bias","volume":"62","author":"Borm","year":"2009","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ejso.2022.04.011_bib9","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/sim.4780081003","article-title":"Group sequential procedures: calendar versus information time","volume":"8","author":"Demets","year":"1989","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.ejso.2022.04.011_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.gie.2021.09.028","article-title":"Trial sequential analysis of EUS-guided gallbladder drainage versus percutaneous cholecystostomy in patients with acute cholecystitis","volume":"95","author":"Cucchetti","year":"2022","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.ejso.2022.04.011_bib11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejso.2022.04.011_bib12","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1349-7006.2010.01793.x","article-title":"Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients","volume":"102","author":"Chuah","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejso.2022.04.011_bib13","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"28","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejso.2022.04.011_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"4\/189","key":"10.1016\/j.ejso.2022.04.011_bib15","article-title":"Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP-05)","volume":"37","author":"Unno","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2022.04.011_bib16","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s11605-015-2890-4","article-title":"Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets","volume":"19","author":"Casadei","year":"2015","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.ejso.2022.04.011_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00066-014-0737-7","article-title":"Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial","volume":"191","author":"Golcher","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ejso.2022.04.011_bib18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","article-title":"Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial","volume":"3","author":"Reni","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejso.2022.04.011_bib19","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2022.04.011_bib20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00423-020-01999-5","article-title":"Meta-analysis and trial sequential analysis of randomised controlled trials comparing standard versus extended lymphadenectomy in pancreatoduodenectomy for adenocarcinoma of the head of pancreas","volume":"406","author":"Kotb","year":"2021","journal-title":"Langenbeck's Arch Surg"},{"key":"10.1016\/j.ejso.2022.04.011_bib21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jclinepi.2005.08.005","article-title":"An unadjusted NNT was a moderately good predictor of health benefit","volume":"59","author":"Chong","year":"2006","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ejso.2022.04.011_bib22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/bjs.11111","article-title":"Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer","volume":"106","author":"Strijker","year":"2019","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2022.04.011_bib23","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2022.04.011_bib24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2022.04.011_bib25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2022.04.011_bib26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.4240\/wjgs.v13.i6.516","article-title":"Borderline resectable pancreatic cancer: certainties and controversies","volume":"13","author":"Nappo","year":"2021","journal-title":"World J Gastrointest Surg"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798322003882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798322003882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:44:34Z","timestamp":1760060674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798322003882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0748798322003882"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2022.04.011","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2022.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}